Q Pang1,2, Y Chi1, Z Zhao1,3, X Xing1, M Li1, O Wang1, Y Jiang1, R Liao1, Y Sun1, J Dong2, W Xia4. 1. Department of Endocrinology, Key Laboratory of Endocrinology, The Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China. 2. Department of Endocrinology, The First affiliated Hospital of Shanxi Medical University, Taiyuan, 030001, China. 3. Department of Geriatrics, Beijing Friendship Hospital affiliated to Capital Medical University, Beijing, 100050, China. 4. Department of Endocrinology, Key Laboratory of Endocrinology, The Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China. xiaweibo@medmail.com.cn.
Abstract
SUMMARY: Osteopetrosis is a group of genetic bone disorders. Mutations in the chloride channel 7 gene (CLCN7) lead to chloride channel defect, which results in autosomal dominant osteopetrosis type II (ADO-II), autosomal recessive osteopetrosis (ARO), and intermediate autosomal recessive osteopetrosis (IARO). In the present study, we identified seven novel mutations of the CLCN7 gene and reported the first case of IARO with compound heterozygous mutation in Chinese population. INTRODUCTION: Osteopetrosis is a heritable bone disorder due to the deficiency of or function defect in osteoclasts. Mutations in the CLCN7 lead to chloride channel defects, which result in osteopetrosis with diverse severity ranging from asymptomatic or relatively mild symptoms in ADO-II to the very severe phenotype in ARO. Heterozygous mutations in CLCN7 are associated to ADO-II, while homozygous and compound heterozygous mutations in CLCN7 may result in ARO and IARO. To date, a total of 24 mutations in CLCN7 were identified in ADO-II, and only 3 mutations were identified in IARO. In the present study, we reported seven unrelated ADO-II patients and one IARO patient from Chinese population and elucidated the characteristics of CLCN7 gene mutations in these patients. METHODS: All 25 CLCN7 exons and exon-intron boundaries from genomic DNA were amplified and sequenced in eight affected individuals suffering from ADO-II/IARO. The clinical, biochemical, and radiographic analysis were evaluated to compare the differences between ADO-II and IARO both in genotype and phenotype. RESULTS: The results showed that there were seven novel CLCN7 mutations identified in these ADO-II/IARO patients, including six heterozygous missense mutations (p.L224R, p.S290Y, p.R326G, p.G347R, p.S473N, and p.L564P) and a novel splice mutation (p.K691FS). CONCLUSIONS: The compound heterozygous mutations (p.L224R and p.K691FS) were firstly observed in one IARO patient. The present study would enrich the database of CLCN7 mutations and improve our understanding of this heritable bone disorder.
SUMMARY:Osteopetrosis is a group of genetic bone disorders. Mutations in the chloride channel 7 gene (CLCN7) lead to chloride channel defect, which results in autosomal dominant osteopetrosis type II (ADO-II), autosomal recessive osteopetrosis (ARO), and intermediate autosomal recessive osteopetrosis (IARO). In the present study, we identified seven novel mutations of the CLCN7 gene and reported the first case of IARO with compound heterozygous mutation in Chinese population. INTRODUCTION:Osteopetrosis is a heritable bone disorder due to the deficiency of or function defect in osteoclasts. Mutations in the CLCN7 lead to chloride channel defects, which result in osteopetrosis with diverse severity ranging from asymptomatic or relatively mild symptoms in ADO-II to the very severe phenotype in ARO. Heterozygous mutations in CLCN7 are associated to ADO-II, while homozygous and compound heterozygous mutations in CLCN7 may result in ARO and IARO. To date, a total of 24 mutations in CLCN7 were identified in ADO-II, and only 3 mutations were identified in IARO. In the present study, we reported seven unrelated ADO-IIpatients and one IARO patient from Chinese population and elucidated the characteristics of CLCN7 gene mutations in these patients. METHODS: All 25 CLCN7 exons and exon-intron boundaries from genomic DNA were amplified and sequenced in eight affected individuals suffering from ADO-II/IARO. The clinical, biochemical, and radiographic analysis were evaluated to compare the differences between ADO-II and IARO both in genotype and phenotype. RESULTS: The results showed that there were seven novel CLCN7 mutations identified in these ADO-II/IARO patients, including six heterozygous missense mutations (p.L224R, p.S290Y, p.R326G, p.G347R, p.S473N, and p.L564P) and a novel splice mutation (p.K691FS). CONCLUSIONS: The compound heterozygous mutations (p.L224R and p.K691FS) were firstly observed in one IARO patient. The present study would enrich the database of CLCN7 mutations and improve our understanding of this heritable bone disorder.
Authors: Ana Belinda Campos-Xavier; Jean-Laurent Casanova; Yves Doumaz; Josué Feingold; Arnold Munnich; Valérie Cormier-Daire Journal: Am J Med Genet A Date: 2005-03-01 Impact factor: 2.802
Authors: Alessandra Pangrazio; Michael Pusch; Elena Caldana; Annalisa Frattini; Edoardo Lanino; Parag M Tamhankar; Shubha Phadke; Antonio Gonzalez Meneses Lopez; Paul Orchard; Ercan Mihci; Mario Abinun; Michael Wright; Kim Vettenranta; Ivo Bariae; Daniela Melis; Ilhan Tezcan; Clarisse Baumann; Franco Locatelli; Marco Zecca; Edwin Horwitz; Lamia Sfaihi Ben Mansour; Mirjam Van Roij; Paolo Vezzoni; Anna Villa; Cristina Sobacchi Journal: Hum Mutat Date: 2010-01 Impact factor: 4.878
Authors: C Letizia; A Taranta; S Migliaccio; C Caliumi; D Diacinti; E Delfini; E D'Erasmo; M Iacobini; M Roggini; O M E Albagha; S H Ralston; A Teti Journal: Calcif Tissue Int Date: 2003-11-26 Impact factor: 4.333
Authors: Sara Penna; Valentina Capo; Eleonora Palagano; Cristina Sobacchi; Anna Villa Journal: Front Endocrinol (Lausanne) Date: 2019-02-19 Impact factor: 5.555